Modulation of α-synuclein aggregation by dopamine: A review

Neurochemical Research

Volumn 34, Issue 10, 2009, Pages 1838-1846

  Leong, Su Ling ^a,b   Cappai, Roberto ^a   Barnham, Kevin Jeffrey ^a,b   Pham, Chi Le Lan ^a,b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

Author keywords

synuclein; Amyloid fibrils; Dopamine; Oligomers; Parkinson's disease

Indexed keywords

ALPHA SYNUCLEIN; DOPAMINE; NEUROMELANIN;

BIOSYNTHESIS; HUMAN; OXIDATION; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW;

ALPHA-SYNUCLEIN; ANIMALS; CELL DEATH; DOPAMINE; HUMANS; NEURONS; OXIDATIVE STRESS; PARKINSON DISEASE; PROTEIN FOLDING;

EID: 69049112795     PISSN: 03643190     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11064-009-9986-8     Document Type: Review

References (79)

1. J Lotharius P Brundin 2002 Pathogenesis of Parkinson's disease: dopamine, vesicles and alpha-synuclein Nat Rev Neurosci 3 932 942 10.1038/nrn983
2. B Thomas MF Beal 2007 Parkinson's disease Hum Mol Genet 16 Review issue 2 R183 R194 10.1093/hmg/ddm159
3. B Pakkenberg A Moller HJ Gundersen, et al. 1991 The absolute number of nerve cells in substantia nigra in normal subjects and in patients with Parkinson's disease estimated with an unbiased stereological method J Neurol Neurosurg Psychiatry 54 30 33 10.1136/jnnp.54.1.30
4. H Braak K Del Tredici U Rub, et al. 2003 Staging of brain pathology related to sporadic Parkinson's disease Neurobiol Aging 24 197 211 10.1016/S0197-4580(02)00065-9
5. MG Spillantini ML Schmidt VM Lee, et al. 1997 Alpha-synuclein in Lewy bodies Nature 388 839 840 10.1038/42166
6. MG Spillantini RA Crowther R Jakes, et al. 1998 Alpha-synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies Proc Natl Acad Sci USA 95 6469 6473 10.1073/pnas.95.11.6469
7. K Wakabayashi K Tanji F Mori H Takahashi 2007 The Lewy body in Parkinson's disease: molecules implicated in the formation and degradation of alpha-synuclein aggregates Neuropathology 27 494 506 10.1111/j.1440-1789.2007. 00803.x
8. MH Polymeropoulos C Lavedan E Leroy, et al. 1997 Mutation in the alpha-synuclein gene identified in families with Parkinson's disease Science 276 2045 2047 10.1126/science.276.5321.2045
9. R Kruger W Kuhn T Muller, et al. 1998 Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease Nat Genet 18 106 108 10.1038/ng0298-106
10. AB Singleton M Farrer J Johnson, et al. 2003 Alpha-synuclein locus triplication causes Parkinson's disease Science 302 841 10.1126/science.1090278
11. JJ Zarranz J Alegre JC Gomez-Esteban, et al. 2004 The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia Ann Neurol 55 164 173 10.1002/ana.10795
12. MC Chartier-Harlin J Kachergus C Roumier, et al. 2004 Alpha-synuclein locus duplication as a cause of familial Parkinson's disease Lancet 364 1167 1169 10.1016/S0140-6736(04)17103-1
13. WS Davidson A Jonas DF Clayton, et al. 1998 Stabilization of alpha-synuclein secondary structure upon binding to synthetic membranes J Biol Chem 273 9443 9449 10.1074/jbc.273.16.9443
14. D Eliezer E Kutluay R Bussell Jr, et al. 2001 Conformational properties of alpha-synuclein in its free and lipid-associated states J Mol Biol 307 1061 1073 10.1006/jmbi.2001.4538
15. S Chandra X Chen J Rizo, et al. 2003 A broken alpha-helix in folded alpha-synuclein J Biol Chem 278 15313 15318 10.1074/jbc.M213128200
16. K Ueda H Fukushima E Masliah, et al. 1993 Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease Proc Natl Acad Sci USA 90 11282 11286 10.1073/pnas.90.23.11282
17. JG Culvenor CA McLean S Cutt, et al. 1999 Non-Abeta component of Alzheimer's disease amyloid (NAC) revisited. NAC and alpha-synuclein are not associated with Abeta amyloid Am J Pathol 155 1173 1181
18. BI Giasson IV Murray JQ Trojanowski, et al. 2001 A hydrophobic stretch of 12 amino acid residues in the middle of alpha-synuclein is essential for filament assembly J Biol Chem 276 2380 2386 10.1074/jbc.M008919200
19. RG Perez JC Waymire E Lin, et al. 2002 A role for alpha-synuclein in the regulation of dopamine biosynthesis J Neurosci 22 3090 3099
20. B Giros MG Caron 1993 Molecular characterization of the dopamine transporter Trends Pharmacol Sci 14 43 49 10.1016/0165-6147(93)90029-J
21. A Abeliovich Y Schmitz I Farinas, et al. 2000 Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system Neuron 25 239 252 10.1016/S0896-6273(00)80886-7
22. KE Larsen Y Schmitz MD Troyer, et al. 2006 Alpha-synuclein overexpression in PC12 and chromaffin cells impairs catecholamine release by interfering with a late step in exocytosis J Neurosci 26 11915 11922 10.1523/JNEUROSCI.3821-06. 2006
23. JE Galvin 2006 Interaction of alpha-synuclein and dopamine metabolites in the pathogenesis of Parkinson's disease: a case for the selective vulnerability of the substantia nigra Acta Neuropathol 112 115 126 10.1007/s00401-006-0096-2
24. D Sulzer J Bogulavsky KE Larsen, et al. 2000 Neuromelanin biosynthesis is driven by excess cytosolic catecholamines not accumulated by synaptic vesicles Proc Natl Acad Sci USA 97 11869 11874 10.1073/pnas.97.22.11869
25. DG Graham SM Tiffany WR Bell, et al. 1978 Autoxidation versus covalent binding of quinones as the mechanism of toxicity of dopamine, 6-hydroxydopamine, and related compounds toward C1300 neuroblastoma cells in vitro Mol Pharmacol 14 644 653
26. L Zecca FA Zucca H Wilms, et al. 2003 Neuromelanin of the substantia nigra: a neuronal black hole with protective and toxic characteristics Trends Neurosci 26 578 580 10.1016/j.tins.2003.08.009
27. E Hirsch AM Graybiel YA Agid 1988 Melanized dopaminergic neurons are differentially susceptible to degeneration in parkinson's disease Nature 334 345 348 10.1038/334345a0
28. M Bisaglia S Mammi L Bubacco 2007 Kinetic and structural analysis of the early oxidation products of dopamine: analysis of the interactions with alpha-synuclein J Biol Chem 282 15597 15605 10.1074/jbc.M610893200
29. SW Li TS Lin S Minteer, et al. 2001 3, 4-dihydroxyphenylacetaldehyde and hydrogen peroxide generate a hydroxyl radical: possible role in Parkinson's disease pathogenesis Brain Res Mol Brain Res 93 1 7 10.1016/S0169-328X(01)00120- 6
30. CLL Pham SL Leong FE Ali, et al. 2009 Dopamine and the dopamine oxidation product 5, 6-dihydroxylindole promote distinct on-pathway and off-pathway aggregation of α-synuclein in a ph-dependent manner J Mol Biol 387 771 785 10.1016/j.jmb.2009.02.007
31. KA Conway JD Harper PT Lansbury 1998 Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease Nat Med 4 1318 1320 10.1038/3311
32. SJ Wood J Wypych S Steavenson, et al. 1999 Alpha-synuclein fibrillogenesis is nucleation-dependent. Implications for the pathogenesis of Parkinson's disease J Biol Chem 274 19509 19512 10.1074/jbc.274.28.19509
33. JD Harper PT Lansbury Jr 1997 Models of amyloid seeding in alzheimer's disease and scrapie: mechanistic truths and physiological consequences of the time-dependent solubility of amyloid proteins Annu Rev Biochem 66 385 407 10.1146/annurev.biochem.66.1.385
34. VN Uversky 2007 Neuropathology, biochemistry, and biophysics of alpha-synuclein aggregation J Neurochem 103 17 37
35. VN Uversky J Li AL Fink 2001 Evidence for a partially folded intermediate in alpha-synuclein fibril formation J Biol Chem 276 10737 10744 10.1074/jbc.M010907200
36. VN Uversky HJ Lee J Li, et al. 2001 Stabilization of partially folded conformation during alpha-synuclein oligomerization in both purified and cytosolic preparations J Biol Chem 276 43495 43498 10.1074/jbc.C100551200
37. W Hoyer T Antony D Cherny, et al. 2002 Dependence of alpha-synuclein aggregate morphology on solution conditions J Mol Biol 322 383 393 10.1016/S0022-2836(02)00775-1
38. VN Uversky J Li AL Fink 2001 Metal-triggered structural transformations, aggregation, and fibrillation of human alpha-synuclein. A possible molecular NK between Parkinson's disease and heavy metal exposure J Biol Chem 276 44284 44296 10.1074/jbc.M105343200
39. VN Uversky G Yamin PO Souillac, et al. 2002 Methionine oxidation inhibits fibrillation of human alpha-synuclein in vitro FEBS Lett 517 239 244 10.1016/S0014-5793(02)02638-8
40. SL Leong CLL Pham D Galatis, et al. 2009 Formation of dopamine-mediated alpha-synuclein-soluble oligomers requires methionine oxidation Free Radic Biol Med 46 1328 1337 10.1016/j.freeradbiomed.2009.02.009
41. VN Uversky G Yamin LA Munishkina, et al. 2005 Effects of nitration on the structure and aggregation of alpha-synuclein Brain Res Mol Brain Res 134 84 102 10.1016/j.molbrainres.2004.11.014
42. G Yamin VN Uversky AL Fink 2003 Nitration inhibits fibrillation of human alpha-synuclein in vitro by formation of soluble oligomers FEBS Lett 542 147 152 10.1016/S0014-5793(03)00367-3
43. R Kayed E Head JL Thompson, et al. 2003 Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis Science 300 486 489 10.1126/science.1079469
44. M Bucciantini E Giannoni F Chiti, et al. 2002 Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases Nature 416 507 511 10.1038/416507a
45. B Caughey PT Lansbury 2003 Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders Annu Rev Neurosci 26 267 298 10.1146/annurev.neuro.26. 010302.081142
46. MP Lambert AK Barlow BA Chromy, et al. 1998 Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins Proc Natl Acad Sci USA 95 6448 6453 10.1073/pnas.95.11.6448
47. KA Conway SJ Lee JC Rochet, et al. 2000 Accelerated oligomerization by Parkinson's disease linked alpha-synuclein mutants Ann N Y Acad Sci 920 42 45
48. KA Conway JD Harper PT Lansbury Jr 2000 Fibrils formed in vitro from alpha-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid Biochemistry 39 2552 2563 10.1021/bi991447r
49. EA Greenbaum CL Graves AJ Mishizen-Eberz, et al. 2005 The E46K mutation in alpha-synuclein increases amyloid fibril formation J Biol Chem 280 7800 7807 10.1074/jbc.M411638200
50. DP Smith DJ Tew AF Hill, et al. 2008 Formation of a high affinity lipid-binding intermediate during the early aggregation phase of alpha-synuclein Biochemistry 47 1425 1434 10.1021/bi701522m
51. SJ Tabrizi M Orth JM Wilkinson, et al. 2000 Expression of mutant alpha-synuclein causes increased susceptibility to dopamine toxicity Hum Mol Genet 9 2683 2689 10.1093/hmg/9.18.2683
52. L Narhi SJ Wood S Steavenson, et al. 1999 Both familial Parkinson's disease mutations accelerate alpha-synuclein aggregation J Biol Chem 274 9843 9846 10.1074/jbc.274.14.9843
53. KA Conway SJ Lee JC Rochet, et al. 2000 Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy Proc Natl Acad Sci USA 97 571 576 10.1073/pnas.97.2.571
54. J Li VN Uversky AL Fink 2001 Effect of familial Parkinson's disease point mutations A30P and A53T on the structural properties, aggregation, and fibrillation of human alpha-synuclein Biochemistry 40 11604 11613 10.1021/bi010616g
55. JC Rochet KA Conway PT Lansbury Jr 2000 Inhibition of fibrillization and accumulation of prefibrillar oligomers in mixtures of human and mouse alpha-synuclein Biochemistry 39 10619 10626 10.1021/bi001315u
56. HA Lashuel D Hartley BM Petre, et al. 2002 Neurodegenerative disease: amyloid pores from pathogenic mutations Nature 418 291 10.1038/418291a
57. HA Lashuel BM Petre J Wall, et al. 2002 Alpha-synuclein, especially the parkinson's disease-associated mutants, forms pore-like annular and tubular protofibrils J Mol Biol 322 1089 1102 10.1016/S0022-2836(02)00735-0
58. MJ Volles PT Lansbury Jr 2002 Vesicle permeabilization by protofibrillar alpha-synuclein is sensitive to Parkinson's disease-linked mutations and occurs by a pore-like mechanism Biochemistry 41 4595 4602 10.1021/bi0121353
59. DL Pountney NH Voelcker WP Gai 2005 Annular alpha-synuclein oligomers are potentially toxic agents in alpha-synucleinopathy. Hypothesis Neurotox Res 7 59 67
60. KM Danzer D Haasen AR Karow, et al. 2007 Different species of alpha-synuclein oligomers induce calcium influx and seeding J Neurosci 27 9220 9232 10.1523/JNEUROSCI.2617-07.2007
61. Emmanouilidou E, Stefanis L, Vekrellis K (2008) Cell-produced alpha-synuclein oligomers are targeted to, and impair, the 26S proteasome. Neurobiol Aging. doi: 10.1016/j.neurobiolaging.2008.07.008
62. R Cappai SL Leck DJ Tew, et al. 2005 Dopamine promotes alpha-synuclein aggregation into SDS-resistant soluble oligomers via a distinct folding pathway FASEB J 19 1377 1379
63. J Li M Zhu AB Manning-Bog, et al. 2004 Dopamine and L-dopa disaggregate amyloid fibrils: implications for Parkinson's and Alzheimer's disease FASEB J 18 962 964 10.1096/fj.04-2273com
64. EH Norris BI Giasson R Hodara, et al. 2005 Reversible inhibition of alpha-synuclein fibrillization by dopaminochrome-mediated conformational alterations J Biol Chem 280 21212 21219 10.1074/jbc.M412621200
65. DM Kuhn RE Arthur Jr DM Thomas, et al. 1999 Tyrosine hydroxylase is inactivated by catechol-quinones and converted to a redox-cycling quinoprotein: possible relevance to Parkinson's disease J Neurochem 73 1309 1317 10.1046/j.1471-4159.1999.0731309.x
66. Y Xu AH Stokes R Roskoski Jr, et al. 1998 Dopamine, in the presence of tyrosinase, covalently modifies and inactivates tyrosine hydroxylase J Neurosci Res 54 691 697 10.1002/(SICI)1097-4547(19981201)54:5<691::AID-JNR14>3.0. CO;2-F
67. RE Whitehead JV Ferrer JA Javitch, et al. 2001 Reaction of oxidized dopamine with endogenous cysteine residues in the human dopamine transporter J Neurochem 76 1242 1251 10.1046/j.1471-4159.2001.00125.x
68. CE Moussa F Mahmoodian Y Tomita, et al. 2008 Dopamine differentially induces aggregation of A53T mutant and wild type alpha-synuclein: insights into the protein chemistry of Parkinson's disease Biochem Biophys Res Commun 365 833 839 10.1016/j.bbrc.2007.11.075
69. JR Mazzulli AJ Mishizen BI Giasson, et al. 2006 Cytosolic catechols inhibit alpha-synuclein aggregation and facilitate the formation of intracellular soluble oligomeric intermediates J Neurosci 26 10068 10078 10.1523/JNEUROSCI.0896-06.2006
70. C Follmer L Romao CM Einsiedler, et al. 2007 Dopamine affects the stability, hydration, and packing of protofibrils and fibrils of the wild type and variants of alpha-synuclein Biochemistry 46 472 482 10.1021/bi061871+
71. KA Conway JC Rochet RM Bieganski, et al. 2001 Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct Science 294 1346 1349 10.1126/science.1063522
72. HT Li DH Lin XY Luo, et al. 2005 Inhibition of alpha-synuclein fibrillization by dopamine analogs via reaction with the amino groups of alpha-synuclein. Implication for dopaminergic neurodegeneration FEBS J 272 3661 3672 10.1111/j.1742-4658.2005.04792.x
73. MJ LaVoie BL Ostaszewski A Weihofen, et al. 2005 Dopamine covalently modifies and functionally inactivates Parkin Nat Med 11 1214 1221 10.1038/nm1314
74. ME Gotz K Double M Gerlach, et al. 2004 The relevance of iron in the pathogenesis of Parkinson's disease Ann N Y Acad Sci 1012 193 208 10.1196/annals.1306.017
75. WJ Burke VB Kumar N Pandey, et al. 2008 Aggregation of alpha-synuclein by DOPAL, the monoamine oxidase metabolite of dopamine Acta Neuropathol 115 193 203 10.1007/s00401-007-0303-9
76. W Zhou A Gallagher DP Hong, et al. 2009 At low concentrations, 3,4-dihydroxyphenylacetic acid (DOPAC) binds non-covalently to alpha-synuclein and prevents its fibrillation J Mol Biol 388 597 610 10.1016/j.jmb.2009.03.053
77. JR Mazzulli M Armakola M Dumoulin, et al. 2007 Cellular oligomerization of alpha-synuclein is determined by the interaction of oxidized catechols with a C-terminal sequence J Biol Chem 282 31621 31630 10.1074/jbc.M704737200
78. FE Herrera A Chesi KE Paleologou, et al. 2008 Inhibition of alpha-synuclein fibrillization by dopamine is mediated by interactions with five C-terminal residues and with E83 in the NAC region PLoS ONE 3 E3394 10.1371/journal.pone.0003394
79. MJ Hokenson VN Uversky J Goers, et al. 2004 Role of individual methionines in the fibrillation of methionine-oxidized alpha-synuclein Biochemistry 43 4621 4633 10.1021/bi049979h